top stories

Dif­fu­sion to hand Nas­daq spot to EIP Phar­ma for PhI­Ib de­men­tia study of ex-Ver­tex drug

4 hours ago
Deals
R&D

Dai­ichi Sankyo inks $183M dis­cov­ery deal with GPCR biotech for CNS tar­get

3 hours ago
Deals
R&D

FDA grants full ap­proval to Keytru­da in tu­mor-ag­nos­tic set­ting; Can­del paus­es tri­al en­roll­ment

2 hours ago
News Briefing

Lu­pus drug de­vel­op­ment mar­ket heat­ing up, while FDA links with ad­vo­ca­cy group to fur­ther ac­cel­er­ate re­search

Just now
Pharma
FDA+

Latest

Most read

In search of new way to de­liv­er gene ed­i­tors, CRISPR pi­o­neer turns to mol­e­c­u­lar sy­ringes

Yesterday
R&D

Mass­a­chu­setts judge dis­miss­es law­suit against Bio­gen over failed launch of Alzheimer's drug Aduhelm

4 minutes ago
Law

Af­ter safe­ty re­view, EMA mir­rors FDA with up­dat­ed rec­om­men­da­tions for JAK in­hibitors

6 minutes ago
R&D

Man­u­fac­tur­ing roundup: Catal­ent to pro­duce low-cost ver­sion of nalox­one; CSL opens R&D site

2 hours ago
Manufacturing

As­pen looks to re­bound in pro­duc­tion and rev­enue af­ter Covid-19

2 hours ago
Manufacturing

Mod­er­na so­lid­i­fies deal with Kenya to build mR­NA man­u­fac­tur­ing fa­cil­i­ty

2 hours ago
Deals
Pharma
see latest stream
People

Alec­tor cuts 11% of work­force as it dou­bles down on late-stage neu­ro pro­grams part­nered with GSK, Ab­b­Vie

7 hours ago

Math­ai Mam­men hands in J&J's R&D keys to lead Greg Ver­dine’s Fog­Phar­ma 

8 hours ago

Q&A: New­ly-mint­ed CSL chief ex­ec­u­tive Paul McKen­zie and chief med­ical of­fi­cer Bill Mez­zan­otte

23 hours ago
Financing

UK gov­ern­ment, pri­vate in­vestors dole out $340M+ to drug, di­ag­nos­tic man­u­fac­tur­ers

23 hours ago

Big Phar­ma-part­nered clin­i­cal tri­al match­mak­er se­cures $20M to im­prove plat­form

23 hours ago

Por­tal In­no­va­tions takes its Chica­go biotech in­vest­ing, lab space mod­el to Boston with Bob Langer start­up in tow

Yesterday
Startups

With Boehringer In­gel­heim’s help, Roivant churns out an­oth­er Vant to go up against En­deav­or, Im­pact founders

2 days ago

Lab­vi­va nets $20M Se­ries A to ease life sci­ence pro­cure­ment process

3 days ago

With one of biotech's largest pri­vate rounds in a year, Ar­riVent en­ters PhI­II

3 days ago
Deals

GSK picks up Scynex­is' FDA-ap­proved an­ti­fun­gal drug for $90M up­front

6 hours ago

Hear­ing-fo­cused biotech grabs trio of pro­grams from Oton­o­my's fire sale

7 hours ago

As­traZeneca ax­es li­cense agree­ment with Aridis, plac­ing Eu­rope-fund­ed PhI­II on hold

Yesterday

Premium storiesSee all

No longer ‘dead or just hi­ber­nat­ing,’ drug­mak­ers re­turn to heart med­i­cines

Yesterday
R&D
In Focus

Q&A: Pfiz­er cor­po­rate com­mu­ni­ca­tions chief Sal­ly Sus­man dis­cuss­es book craft­ed in pan­dem­ic and per­son­al lessons

2 days ago
Pharma
Marketing

Jef­frey Blue­stone brings his start­up haul to $400M+, join­ing forces with Re­gen­eron on cell ther­a­pies

2 days ago
Financing
Bioregnum

Who’s spend­ing and who’s cut­ting from Big Phar­ma’s $127B R&D bud­get? Here are the top 15 play­ers

3 days ago
R&D
Special

In FocusSee all

Rare dis­ease tri­als can't find enough pa­tients. It's forc­ing the FDA to re­think its ap­proach

4 weeks ago
FDA+

‘Hard­er to find homes’: Lat­est wave of biotech lay­offs could test the in­dus­try

4 weeks ago
People

A ra­dioac­tive prostate can­cer ther­a­py is a last life­line for pa­tients. No­var­tis can't make enough of it

5 weeks ago
R&D

Decades af­ter break­through, sci­en­tists still puz­zling over mR­NA de­liv­ery

5 weeks ago
R&D

Don't missSee all

J&J bows out of RSV vac­cine race, end­ing PhI­II study and ced­ing to Pfiz­er, GSK

Yesterday
R&D
Pharma

Phar­ma ad to­tal tops $8B again in 2022, led by top brands from Sanofi and Re­gen­eron, Ab­b­Vie

Yesterday
Pharma
Marketing

Mar­ket­ingRx roundup: Ab­b­Vie dri­ves en­dometrio­sis aware­ness; No­var­tis adds to Cosen­tyx cam­paign

2 days ago
Pharma
Marketing

Tiny mul­ti­omics biotech se­cures for­mer J&J drug, new ex­ecs and new fi­nanc­ing

2 days ago
Financing
R&D

Endpoints Standouts

Sci­en­tists are fi­nal­ly learn­ing how to de­sign pro­teins from scratch. Drug de­vel­op­ment may nev­er be the same

10 months ago
People
Discovery

The 20(+1) un­der 40: Your guide to the next gen­er­a­tion of biotech lead­ers

11 months ago
Special

The 2022 top 100 bio­phar­ma in­vestors: A look back on boom times

Last year
Financing
Deals

Spe­cial re­port: Meet 20 ex­tra­or­di­nary women who are su­per­charg­ing bio­phar­ma R&D

Last year
People
Special

Peer review See all

Mar
24

Three­'s a crowd as an­oth­er Kite ex­ec hits the ex­it; Surf­ing tough wa­ters, Celyad On­col­o­gy picks up new CEO

Mar
17

Ul­tragenyx adds new CMO with in­ter­nal pro­mo­tion; Au­to­lus CFO to leave for Mor­phoSys — but not quite yet

Mar
10

Bio­gen looks to its bench to re­place chair­man Pa­padopou­los; Lil­ly, Ab­b­Vie gene ther­a­py part­ner makes CSO hire

Mar
3

Kymer­a's top drug hunter leaves for Alex­is Borisy's Curie.Bio; What’s done is Dunn: FDA neu­ro­science leader bows ...

Feb
24

Art Levin trades the C-suite for pair of roles at Avid­i­ty; Ex-Mer­ck CEO Ken Fra­zier to chair an­oth­er com­pa­ny

Pharma channel feed

2 days ago

Gun­ning for 2023 ap­proval, GSK de­tails PhI­II da­ta for Jem­per­li in front­line en­dome­tri­al can­cer

GSK has a new slate of da­ta to of­fer on its PD-1 in­hibitor, Jem­per­li — da­ta that the phar­ma gi­ant hopes will ce­ment one of the four drug ap­provals it’s ex­pect­ing this year.

READ MORE

Es­pe­ri­on sues Dai­ichi Sankyo, de­mand­ing pay­ment of $300M mile­stone for car­dio drug

2 days ago
Law

Eli Lil­ly to in­crease in­vest­ment to $1B in­to new Irish man­u­fac­tur­ing fa­cil­i­ty — re­port

2 days ago
Manufacturing
latest in Pharma

Ther­mo Fish­er moves on cam­pus with new cell man­u­fac­tur­ing site in San Fran­cis­co

2 hours ago
Manufacturing

Ot­su­ka, Lund­beck eye Alzheimer's in­di­ca­tion in FDA ad­comm for Rex­ul­ti la­bel ex­pan­sion

23 hours ago

Ohio at­tor­ney gen­er­al sues sev­er­al PBMs over an­titrust con­cerns

Yesterday
Law

House com­mit­tee to in­ves­ti­gate FDA's re­sponse to on­go­ing drug short­ages

2 days ago
FDA+
Manufacturing

Evotec’s CNS deal with Bris­tol My­ers gets $50M in­fu­sion and eight-year ex­ten­sion

2 days ago
Deals
see latest stories

Marketing channel feed

23 hours ago

Boehringer re­ports ro­bust sales led by type 2 di­a­betes and pul­monary drugs, promis­es more to come high­light­ing obe­si­ty

Boehringer In­gel­heim re­port­ed hu­man phar­ma sales of €18.5 bil­lion on Wednes­day, led by type 2 di­a­betes and heart fail­ure drug Jar­diance and pul­monary fi­bro­sis med Ofev. Jar­diance sales ...

READ MORE

FDA ap­proves Nar­can opi­oid over­dose re­ver­sal spray for over-the-counter sale

Yesterday
Pharma
FDA+

Eu­ro­pean doc­tors di­al up dig­i­tal com­mu­ni­ca­tion with phar­mas, but still lean to­ward in-per­son med meet­ings, study ...

5 days ago
Pharma
latest in Marketing

Ab­bott in­tro­duces the Mel­on fam­i­ly to raise con­cus­sion aware­ness

6 days ago
Pharma

Take­da and Lund­beck change tac­tics on Trin­tel­lix de­pres­sion cam­paign

6 days ago
Pharma

Bris­tol My­ers’ ‘Liv­ing’ doc­u­men­tary ties to­geth­er peo­ple man­ag­ing health con­di­tions

6 days ago
Pharma

So­cial me­dia pa­tient in­flu­encers ‘danc­ing in the gray’ of phar­ma mar­ket­ing, more clar­i­ty need­ed, re­searcher says

Last week
Pharma

No­vo Nordisk re­mains un­der UK scruti­ny as MHRA con­ducts its own re­view in 'in­cred­i­bly rare' case

Last week
Pharma
see latest stories

FDA+ channel feed

3 days ago

Brain­Storm gets FDA ad­comm for ALS drug af­ter failed tri­al and RTF

Brain­Storm Cell Ther­a­peu­tics has had a rocky road try­ing to get its ALS treat­ment through to the FDA, in­clud­ing a par­tic­u­lar­ly dif­fi­cult set­back af­ter the FDA slapped the com­pa­ny with a ...

READ MORE

Eu­ro­pean Com­mis­sion de­lays pro­pos­al for ma­jor changes to phar­ma leg­is­la­tion

6 days ago
Pharma

FDA lifts par­tial clin­i­cal hold on Vig­il Neu­ro­science's TREM2 an­ti­body, re­mov­ing dos­ing cap

3 hours ago
latest in FDA+

Blue­bird to miss Q1 dead­line for lo­vo-cel fil­ing, shares sliced

Yesterday

FDA lifts par­tial hold on Blue­print­'s CDK2 in­hibitor

Yesterday

House com­mit­tee chair re­quests in­fo from FDA on fund­ing for tri­als in­volv­ing 'vi­ral ma­nip­u­la­tion'

Yesterday
Law

FDA plans up­com­ing ad­comms for OTC con­tra­cep­tive, ep­i­neph­rine nasal spray, Intar­ci­a's last shot

Yesterday

Up­dat­ed: FDA ap­proves Pharm­ing drug for ul­tra-rare im­mun­od­e­fi­cien­cy dis­ease

5 days ago
R&D
see latest stories

Manufacturing channel feed

23 hours ago

Phar­maron ex­pand­ing Liv­er­pool man­u­fac­tur­ing fa­cil­i­ty with a $186M+ price tag

Liv­er­pool may be known for rock and roll and pre­mier league foot­ball, but the Chi­na-based con­tract man­u­fac­tur­er Phar­maron is look­ing to make it a big­ger hub for cell and gene ther­a­py ...

READ MORE

Deer­field Dis­cov­ery nets $50M grant from the state of New York and par­ent com­pa­ny

Yesterday
Financing
Discovery

Re­silience notch­es $410M in fed­er­al fi­nanc­ing to bol­ster pro­duc­tion

3 days ago
Financing
Pharma
latest in Manufacturing

Q&A: BioCi­na’s new CEO Mark Wom­ack on the CD­MO he says is 'worth trav­el­ing over'

5 days ago
People

White House un­veils ‘bold goals’ for US bio­man­u­fac­tur­ing ef­forts

Last week
Pharma

Con­tract man­u­fac­tur­er Cu­ria names new CEO

Last week
People

Take­da in­vests $760M+ in­to new plas­ma-de­rived ther­a­py man­u­fac­tur­ing site in Japan

Last week
Pharma

Man­u­fac­tur­ing roundup: Cana­da to in­vest $58M+ in­to 'crit­i­cal' med­i­cines man­u­fac­tur­ing; FDA to ac­cept apps for CMC pi­lot

Last week
see latest stories